Core Viewpoint - The article discusses the efficacy of Tirofiban, a platelet glycoprotein IIb-IIIa receptor antagonist, in improving functional outcomes for patients with acute ischemic stroke who receive intravenous thrombolysis within 4.5 hours of symptom onset [3][11]. Group 1 - Intravenous thrombolysis remains the standard treatment for acute ischemic stroke within 4.5 hours, and the use of antiplatelet drugs may prevent reocclusion in the first 24 hours post-thrombolysis [2]. - The ASSET-IT trial, published in NEJM, involved 832 patients with non-cardiogenic stroke who received thrombolysis and assessed the impact of early Tirofiban infusion on functional outcomes [3][10]. - The study was led by Professor Wei Hu from the First Affiliated Hospital of the University of Science and Technology of China, with contributions from multiple co-authors [6]. Group 2 - The trial was a multicenter, double-blind, randomized controlled study conducted across 38 medical centers in China, focusing on patients who were not candidates for thrombectomy [9]. - Patients were randomly assigned to receive either Tirofiban or a placebo within 60 minutes after thrombolysis, with the primary outcome being the proportion of patients achieving a good functional outcome at 90 days [10]. - Results indicated that 65.9% of the Tirofiban group achieved a good functional outcome compared to 54.9% in the placebo group, with a hazard ratio of 1.20 [11]. Group 3 - The incidence of symptomatic intracranial hemorrhage was 1.7% in the Tirofiban group versus 0% in the placebo group, while the mortality rate at 90 days was 4.1% for Tirofiban and 3.8% for placebo [11]. - The study fills an evidence gap regarding the use of antiplatelet drugs in the post-thrombolysis window for stroke patients, providing high-quality evidence to optimize treatment strategies in China [12].

Core Insights - The article highlights significant research advancements published in the journal Cell, with a focus on studies led by Chinese scholars, covering topics such as organoid development, vascular dementia mechanisms, autoimmune disease treatments, and the role of synonymous mutations in cucumber domestication [2][4][8][12][17]. Group 1: Highly Vascularized Lung and Gut Organoids - A collaborative study from Cincinnati Children's Hospital and UCLA successfully constructed highly vascularized lung and gut organoids using human induced pluripotent stem cells (iPSCs), providing a platform for studying organ development and disease [4]. Group 2: Mechanisms of Vascular Dementia Repair - Research from UCLA identified key signaling pathways involved in brain repair for vascular dementia, specifically the CD39-A3AR pathway, and demonstrated that the A3AR agonist Piclidenoson could promote brain tissue repair and restore memory and gait functions [8]. Group 3: LAG-3/TCR Dual Antibody for Autoimmune Diseases - A study from NYU and Chinese institutions revealed a novel mechanism of LAG-3 receptor activation, which could lead to the development of dual-specific T cell inhibitory antibodies targeting LAG-3 and TCR, offering new therapeutic avenues for autoimmune diseases [12][13]. Group 4: Synonymous Mutations in Cucumber Domestication - Research from the Chinese Academy of Agricultural Sciences demonstrated that synonymous mutations can regulate important traits in cucumber domestication through epitranscriptomic mechanisms, challenging traditional views and suggesting new strategies for crop improvement [17].

Core Viewpoint - Ferroelectric materials are crucial for various electromechanical devices due to their excellent piezoelectric properties, enabling efficient conversion between electrical and mechanical energy [2][3][5]. Group 1: Development and Applications - Over the past century, a variety of ferroelectric materials have been developed, including lead zirconate titanate ceramics, lead-free ceramics, aluminum nitride films, and ferroelectric polymers based on polyvinylidene fluoride [2]. - These innovations have expanded the range of applications for ferroelectric materials and provided greater flexibility in device design, benefiting numerous piezoelectric devices such as cooling fans in smartphones and ultrasound transducers [2][5]. - The review paper published by Professor Li Fei highlights the reliance of small electromechanical devices, like speakers and motors in smartphones, on ferroelectric materials, which deform under an electric field [3]. Group 2: Research Progress and Future Directions - Recent research has focused on enhancing the piezoelectric performance of ferroelectric materials, proposing strategies to meet the growing demand for high-performance piezoelectric devices and systems [6]. - The review also emphasizes the need to consider the environmental impact of ferroelectric materials throughout their lifecycle, from raw material acquisition to manufacturing, usage, and disposal [6]. Group 3: Market Relevance - The current and emerging piezoelectric devices in the 3C (computer, communication, and consumer electronics) sector illustrate the diversity of piezoelectric applications, particularly in consumer electronics like smartphones [8].

Core Viewpoint - The establishment of a protein drug design research group at Shenzhen Medical Academy by Dr. Yang Wei, focusing on innovative protein-protein interaction design methods for cancer immunotherapy [2][3]. Group 1: Research Background - Dr. Yang Wei obtained his Ph.D. in Biology from Tsinghua University in 2019 and has conducted postdoctoral research at the University of Washington, collaborating with notable figures in protein design [2]. - His research emphasizes the development of new computational design methods for protein interactions, particularly in the context of immune regulation and cancer immunotherapy [2][3]. Group 2: Research Objectives - The protein drug design group aims to create new drug design methods and validation platforms to support the development of novel protein drugs [3]. - The group will focus on designing highly selective biomolecules for cancer immunotherapy, enhancing targeting while reducing systemic toxicity [3]. Group 3: Recent Research Publication - On February 26, 2025, Dr. Yang published a paper in Nature Communications titled "Design of high-affinity binders to immune modulating receptors for cancer immunotherapy," detailing his research direction [5]. - The study highlights the importance of immune receptors in maintaining internal balance and their role in cancer immunotherapy, which has significantly improved patient survival rates [9]. Group 4: Targeted Protein Design - The research team is developing a specialized 5-helix concave scaffold (5HCS) to create high-affinity protein binders targeting key immune receptors involved in cancer therapy, such as TGFβRII, CTLA-4, and PD-L1 [10][11]. - The designed protein binders have shown low nanomolar to picomolar affinity and strong biological activity, indicating their potential for therapeutic applications [11].

Core Viewpoint - The emergence of large language models (LLMs) like ChatGPT has significantly transformed academic writing, particularly in the biomedical field, raising concerns about research integrity and the accuracy of generated content [2][5]. Group 1: Impact of LLMs on Academic Writing - A study published in July 2025 revealed that approximately 200,000 out of 1.5 million biomedical papers indexed by PubMed in 2024 showed signs of LLM-generated text, accounting for about 1/7 of the abstracts [3][4]. - The use of LLM-assisted writing in biomedical publications is accelerating, with an earlier assessment indicating that about 1/9 of abstracts in the first half of 2024 exhibited similar signs [4]. - The study found that at least 13.5% of abstracts in 2024 were processed using LLMs, with some sub-corpora reaching as high as 40%, indicating a profound impact on scientific writing [5][10]. Group 2: Methodology and Findings - Researchers analyzed over 15 million abstracts from PubMed between 2010 and 2024, identifying 454 words that appeared significantly more frequently in 2024 compared to previous years, many of which were stylistic rather than content-related [7][9]. - The study highlighted that the vocabulary changes were more pronounced following the rise of LLMs than during significant events like the COVID-19 pandemic, with a notable increase in the use of adjectives and verbs [9][10]. - The proportion of LLM-assisted writing varies across disciplines, countries, and journals, with over 20% of abstracts in certain regions and fields utilizing LLMs [10]. Group 3: Challenges and Adaptations - Previous attempts to assess the impact of LLMs on academic writing faced challenges due to the lack of disclosure from users, making it difficult to evaluate the true extent of LLM usage [6]. - As authors become aware of specific vocabulary associated with AI-generated text, such as "delves," its usage may decline, complicating the assessment of AI's influence on academic writing [12]. - While using AI for text refinement or translation is deemed reasonable, generating large volumes of text without oversight raises concerns regarding research integrity [13].

撰文丨王聪 编辑丨王多鱼 排版丨水成文 肺癌 是全球癌症相关死亡的首要原因。对于能够检测特定基因突变以实现靶向治疗且经济实惠、无创的方法的需求，以及预测患者生存结果的需求，凸显了提升 诊断和预后能力的重要性。当前的肺癌诊断模型常常无法整合多样化的患者数据，导致临床评估不全面。 2025 年 7 月 2 日， 温州医科大学附属第一医院 黄晓颖 教授、 北京大学未来技术学院 王劲卓 、温州医科大学 张康 、四川大学华西医院 王成弟 等，在 Cell 子刊 Cell Reports Medicine 上发表了题为 ： AI-enabled molecular phenotyping and prognostic predictions in lung cancer through multimodal clinical information integration 的研究论文。 该研究开发了一款多模态 集成 AI 模型 —— LUCID ， 通过多模态临床信息整合，实现了肺癌分子表型分析及预后预测。 除了突变识别之外，准确的生存时间预测仍是优化肺癌治疗策略的关键组成部分。这种预后信息使临床医生能够制定更个性化的治 ...

Core Viewpoint - The research highlights that chemotherapy can awaken dormant disseminated tumor cells (DTCs) in lung cancer, leading to metastatic recurrence, and proposes a novel combination therapy strategy to inhibit this process [2][4][8]. Group 1: Research Findings - The study established a dormant tumor cell lineage tracing system called DormTracer, confirming that dormant DTCs can be reactivated by chemotherapy, resulting in metastatic recurrence [5][6]. - Chemotherapy drugs, including doxorubicin and cisplatin, enhance the proliferation and lung metastasis of dormant breast cancer cells [4][6]. - The mechanism involves chemotherapy inducing senescence in fibroblasts, which promotes the formation of neutrophil extracellular traps (NETs) that facilitate the proliferation of dormant DTCs [5][6]. Group 2: Proposed Treatment Strategy - The research suggests a new combined treatment strategy using senolytic drugs (dasatinib + quercetin) alongside chemotherapy to inhibit the reactivation of dormant DTCs and suppress tumor metastasis [5][6][8]. - This combination therapy aims to improve treatment outcomes by addressing the adverse effects of chemotherapy on cancer metastasis [8].

长期以来，人们一直认为肺癌是吸烟者的疾病。然而，随着世界许多国家和地区的烟草使用量的下降，一个令人担忧的趋势出现了： 从不吸烟者患肺癌的比例正 在上升 。 撰文丨王聪 编辑丨王多鱼 排版丨水成文 肺癌 是全世界发病率最高的癌症 ，也是全世界癌症死亡的最主要原因，据 世界卫生组织国际癌症研究机构 （IARC） 于 2024 年 发布的最新评估数据，肺癌每 年新增 248 万例，导致 180 万人死亡 。 从不吸烟者肺癌 （LCINS） 约占所有肺癌病例的 25%，这类肺癌对女性的影响尤为严重，尤其是亚裔女性，而且在东亚国家比在西方国家更为普遍。 一项发表于 Nature 期刊的最新研究，提供了令人信服的基因组证据，表明了 空气污染、 传统中草药以及其他环境因素是从不吸烟者肺癌的主要潜在因素。 | 国际顶尖学术期刊 | Nature | 。论文通讯作者为美国国家癌症研究所 | Maria Teresa Landi | | 研究员和加州大学圣地 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 该研究以： 亚哥分校 | The mutagenic f ...

Core Viewpoint - The discovery of 35 well-preserved wooden tools at the Gantangqing site in Yunnan, China, dating back approximately 300,000 years, indicates that wooden tools played a significant role in the survival and adaptation of early humans in East Asia during the Middle Pleistocene [2][8]. Group 1: Discovery and Significance - The Gantangqing site is the first Middle Pleistocene open-air site discovered in Yuxi, Yunnan, providing valuable materials for comparative studies of early Paleolithic culture in China [4]. - The wooden tools found at the site fill a gap in the study of wooden artifacts from the Paleolithic era in China, highlighting their importance in early human culture [4][12]. Group 2: Tool Characteristics and Usage - The 35 wooden tools include digging sticks and small handheld pointed tools, showcasing a complexity that contrasts with the seemingly "primitive" stone tool assemblages of early East Asian Paleolithic [6][7]. - Evidence of human processing is found on some tools, including wear patterns and soil residues containing plant starch grains, confirming their primary function for digging underground plant food [7][12]. Group 3: Broader Implications - This research suggests that wooden tools were crucial for early human survival strategies in tropical and subtropical environments, revealing unique resource utilization strategies [12]. - The findings challenge previous notions that early wooden tools were primarily hunting implements, indicating a broader range of uses, particularly in plant-based food processing [12].

Core Viewpoint - Tirzepatide, developed by Eli Lilly, is a dual agonist for GIP and GLP-1 receptors, recently approved by the FDA for weight loss under the brand name Zepbound™ and previously for type 2 diabetes as Mounjaro™. It is noted as the most effective weight loss drug currently available, having set multiple records in clinical trials for weight reduction [2]. Summary by Sections FDA Approval and Indications - Tirzepatide received FDA approval in November 2023 for weight loss and has also been approved for type 2 diabetes treatment. It has now gained a third indication for moderate to severe obstructive sleep apnea (OSA) in adults, as announced by the NMPA in China [2]. Clinical Trial Results - The SURMOUNT-OSA trial demonstrated that Tirzepatide significantly reduced the apnea-hypopnea index (AHI) and body weight in patients with moderate to severe OSA and obesity. In a 52-week treatment period, patients lost an average of 20% of their body weight, and AHI decreased by an average of 27 times per hour [2][7][11]. Efficacy Metrics - In the SURMOUNT-OSA study, patients treated with Tirzepatide experienced a 55% reduction in AHI compared to a 5% reduction in the placebo group. The average weight loss in the Tirzepatide group was 18.1%, while the placebo group saw only a 1.3% reduction [8][9]. Safety Profile - The overall safety of Tirzepatide in the SURMOUNT-OSA studies was consistent with previous trials, with gastrointestinal issues being the most commonly reported adverse events, generally mild to moderate in severity [12]. Market Potential - The success of the SURMOUNT-OSA trials indicates a significant advancement in addressing the unmet clinical need for OSA treatment, positioning Tirzepatide as a potential first pharmacological therapy for this condition [12]. Demographics of Study Participants - Approximately 70% of participants in the studies were male, with evidence suggesting that Tirzepatide may have a more pronounced weight loss effect in females [11].